Drug intelligence / Profile preview

SUVN-M8036

Development stage: Preclinical
Lead developer: Suven Life Sciences
Modality: Small Molecules

Overview

SUVN-M8036 is a small molecule drug candidate being developed by Suven Life Sciences for the treatment of psychiatric disorders. It acts as a multimodal modulator of the serotonergic and dopaminergic systems, targeting neurochemical pathways involved in various mental health conditions. As of early 2025, the compound is in the preclinical stage of development, having been recently added to the company's CNS-focused research pipeline. Specific receptor subtype profiles have not yet been publicly disclosed, but the drug is designed to address imbalances in serotonin and dopamine signaling.

Targets

HTR7 (5-hydroxytryptamine receptor 7)HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on SUVN-M8036.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SUVN-M8036.

Explore the full profile